|
|
|
| Clinical significance of changes in serum cysC levels in patients with liver disease |
| DING Tianpeng,SHI Genlin,SUN Qingming,and ZHU Feng |
| .Jiangsu Provincial Corps Hospital ,Chinese People’s Armed Police Forces, Yangzhou,225003,China |
|
|
|
|
Abstract Objective To study the changes in serum cystatin C (Cys C) levels in patients with liver disease. Methods The levels of serum Cys C,alanine aminotransferase enzyme (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL),gama-glutamyl transferase (GGT) were assayed in patients with normal serum creatinine（CERA） concentration, including 61 patients with chronic hepatitis,22 patients with severe hepatitis,43 patients with hepatocirrhosis,26 patients with hepatocarcinoma and 50 healthy subjects. And the relationship between Cys C and ALT, AST, TBIL, GGT,PT,and the change, of serum CysC before and after the treatment of liver disease was analyzed. Results The levels of serum Cys C were 1.12±0.26 mg/L,1.32±0.36 mg/L,1.54±0.24 mg/L,1.38±0.30 mg/L, and 0.76±0.15 mg/L in chronic hepatitis group, severe hepatitis group, hepatocirrhosis group, hepatocarcinoma group, and control group, respectively .The level of serum CysC was significantly higher in all the liver disease group compared with the control group (P<0.01), It was significantly higher in severe hepatitis group, hepatocirrhosis group and hepatocarcinoma group than in the chronic hepatitis group (P<0.05). It was markedly higher in the hepatocirrhosis group than in the severe hepatitis group (P<0.05).There was no statistically significant difference between hepatocirrhosis group and the hepatocarcinoma group (P>0.05).There was positive relationship between CysC and ALT, AST,TBIL,GGT(P<0.05). There is no significant variation of the level of serum CysC in liver disease patients after treatment(P>0.05). Conclusions The level of serum CysC is significantly higher in patients with liver disease,which is considered as a precise index for liver function evaluation and has significant reference value for monitoring the progression of liver disease.
|
|
Received: 13 September 2012
|
|
|
|
|
|
|
|
|
2013, Vol. 24 
